The Oncologic Drug Advisory Committee (ODAC) of the US Food and Drug Administration has provided a positive opinion on Mylotarg (gemtuzumab ozogamicin).
The advisory panel determined that, based on data from the pivotal ALFA-0701 study, the drug candidate has a favorable risk/benefit profile as an adjunctive therapy for certain newly-diagnosed acute myeloid leukemia (AML) patients.
The drug is an antibody-drug conjugate under development by New York-based Pfizer (NYSE: PFE), comprised of a cytotoxic agent attached to a monoclonal antibody.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze